Regeneron Pharmaceuticals (REGN)
EBITDA Growth
0.31%
Quarterly · Period ending:
REGN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported0.31%period ending
Latest reported0.31%period ending
REGN Quarterly EBITDA YoY % (66.67% → 0.31%)
Year-over-year change
High-resolution chart · PNG
REGN ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -487.4515% | |
| -77.1512% | |
| -4,207% | |
| -241.2619% | |
| 62.1733% | |
| 22.1237% | |
| 103.6364% | |
| -147.0588% | |
| -600% | |
| -142.5% | |
| -339.1304% | |
| -1,600% | |
| 160% | |
| -37.931% | |
| 179.3103% | |
| 96.5517% | |
| -13.6364% | |
| 9.375% | |
| -107.1429% | |
| -262.5% | |
| -1,200% | |
| -540% | |
| 64.1026% | |
| 69.2308% | |
| 102.2222% | |
| 94.7368% | |
| 62.1359% | |
| 69.4118% | |
| 1.0989% | |
| -11.7647% | |
| -87.2727% | |
| -66.6667% | |
| -203.3333% | |
| -203.5714% | |
| -61.7647% | |
| -121.7391% | |
| -66.6667% | |
| -240% | |
| 51.4286% | |
| -276.9231% | |
| -250% | |
| 66.6667% |